



Test Definition: FHTGF

Human Transforming Growth Factor beta 1
(TGF-b1)

Overview

Method Name

ELISA

NY State Available

Yes

Specimen

Specimen Type

Plasma EDTA

Specimen Required

Specimen Type: Platelet-free Plasma

Container/Tube: Lavender top (EDTA)

Specimen Volume: 1 mL

Collection Instructions:

1. Draw blood in a lavender top (EDTA) tube.
2. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Centrifuge plasma again at 3000 x g for 10 minutes for complete platelet removal.
3. Aliquot plasma into a plastic vial and freeze at -20 degrees C or below.
4. Send 1 mL platelet-free plasma frozen in plastic vial.

Additional Information:

For fixed speed centrifuges such as 645e: Within 30 minutes of collection, centrifuge 3 times for 10 minutes at 1600 x g while decanting the plasma each time before the next centrifugation. Aliquot plasma into a plastic vial and freeze at -20 degrees C or below.

Specimen Minimum Volume

0.25 mL

Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Specimens with particulate matter or	Reject

microbial contamination Specimens outside of listed stability Samples submitted without two unique identifiers and date of collection	
---	--

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Plasma EDTA	Frozen	14 days	

Clinical & Interpretive

Clinical Information

Transforming growth factor (TGF) play a crucial role in tissue regeneration, cell differentiation, embryonic development, and regulation of the immune system. Transforming growth factor beta is found in hematopoietic (blood-forming) tissue and initiates a signaling pathway that suppresses the early development of cancer cells. It enhances the deposition of extracellular matrix and may play potential role in wound healing and cirrhosis formation. Many cells synthesize TGF-b and almost all of them have specific receptors for this peptide.

Reference Values

0-22,062 pg/mL

Performance

Method Description

This quantitative assay employs sandwich ELISA method. Microwells are pre-coated with antibodies against TGF-b1. The diluted patient samples (after activation) are added into the wells and any TGF-b1 present remains bound to the plate. After washing the wells, peroxidase labeled anti-TGF-b1 antibodies are added. Bound conjugate is visualized with TMB substrate and intensity of color is proportional to the concentration of TGF-b1 in the sample. Stop dilution is added to each well to stop the reaction.

PDF Report

No

Day(s) Performed

Varies, 2 days per week

Report Available

6 to 14 days

Performing Laboratory Location

BioAgilytix Diagnostics

Fees & Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

The performance characteristics of the listed assay was validated by BioAgilytix Diagnostics. The US FDA has not approved or cleared this test. The results of this assay can be used for clinical diagnosis without FDA approval. BioAgilytix Diagnostics is a CLIA certified, CAP accredited laboratory for performing high complexity assays such as this one.

CPT Code Information

83520

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
FHTGF	Human Transforming Growth Factor b1	Not Provided

Result ID	Test Result Name	Result LOINC® Value
Z6269	TGF-b1	Not Provided